Related Experiment Video
Updated: Jan 16, 2026
Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
Gut microbiota mediates the protective effects of SGLT-2 inhibitors on bipolar disorder: An intermediary Mendelian
Yaofeng Wang1, Yunchang Yang1, Yunqin Sun1
1North Henan medical university, Xinxiang,China.
Background:
Bipolar disorder (BD), with a global prevalence of approximately 1%, is characterized by mood swings and social impairment, and involves factors such as genetics, brain structure abnormalities, and gut-brain axis dysregulation OBJECTIVES: The influence of SGLT-2 inhibitors and gut microbiota on BD remains unclear. We Investigate causal links between SGLT-2 inhibitors, gut microbiota, and BD risk using Mendelian randomization (MR). Identify mediating microbiota and elucidate connecting molecular pathways.
Methods:
Two-sample MR utilized European GWAS data. Instrumental variables (p < 5 × 10⁻⁵ for microbiota/BD) were analyzed primarily via inverse-variance weighted regression, with sensitivity analyses. Mediation analysis assessed SGLT-2 effects via microbiota. Functional enrichment (GO/KEGG), gene expression (GSE5388), and PPI network analyses identified pathways and hub genes.
Results:
SGLT-2 inhibitors showed a significant negative causal effect on BD risk (OR = 0.104, 95% CI: 0.048-0.228, p < 0.001), partially mediated by Clostridium sporosphaeroides abundance (proportion mediated = 4.1%; statistically significant at a nominal p-value threshold, though not after multiple testing correction. 368 of the 473 gut microbiota taxa showed evidence of a causal association with BD. Enrichment implicated calcium signaling (p < 0.001) and neuroactive ligand-receptor pathways. Differential expression identified dysregulated GANC (p = 0.048) in BD frontal cortices. PPI networks revealed hub genes (COQ2, PKM) involved in mitochondrial function and GPCR activity.
Conclusions:
This study provides genetic evidence that SGLT-2 inhibitors may reduce BD risk, partly modulated by Clostridium sporosphaeroides. Identified pathways (e.g., calcium signaling) and dysregulated genes highlight mecolic-immune interplay in BD. Findings support evaluating SGLT-2 inhibitors and microbiota therapies in BD, though European-centric data requires broader validation.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists